Publication Name	World Journal of Gastroenterology
Manuscript ID	27006
Country	Canada

Received	2016-05-04 08:58
Peer-Review Started	2016-05-04 15:42
To Make the First Decision	2016-05-27 11:09
Return for Revision	2016-05-27 15:38
Revised	2016-05-31 02:13
Second Decision	2016-06-02 10:15
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2016-06-13 18:14
Articles in Press	2016-06-13 18:14
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2016-06-26 17:00
Publish the Manuscript Online	2016-07-04 14:42

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Infectious Diseases
Manuscript Type	Editorial
Article Title	Symbiotic chemo- and immuno-therapy for hepatitis B and C viruses
Manuscript Source	Invited Manuscript
All Author List	Babita Agrawal and Rakesh Kumar
Funding Agency and Grant Number
Corresponding Author	Dr. Rakesh Kumar, Professor, Depart­ment of Laboratory Medicine and Pathology, Faculty of Medicine and Dentistry, University of Alberta, 116 St and 85 Ave, Edmonton, AB T6G 2R3, Canada. rkumar@ualberta.ca
Key Words	Hepatitis C virus; Hepatitis B virus; Direct-acting antiviral; Chemotherapy; Immunotherapy
Core Tip	Immune related mechanisms have been shown to eliminate both Hepatitis B and C viruses (HBV and HCV) from chronically infected host cells via non-cytolytic mechanisms. Current direct-acting antivirals against replication of both HBV and HCV are effective and provide significant viral suppression in a relatively short period of time. This time window should be harnessed to target host-mediated immune mechanisms to clear the host of the infection. This strategy would lead to a significant reduction in cost, duration, side effects and development of resistance associated with direct-acting antivirals therapy. In summary, regimens combining chemo- and immuno-therapy must be used in a mutually beneficial manner to eradicate HBV and/or HCV from a host.
Publish Date	2016-07-04 14:42
Citation	Agrawal B, Kumar R. Symbiotic chemo- and immuno-therapy for hepatitis B and C viruses. World J Gastroenterol 2016; 22(25): 5623-5626
URL	http://www.wjgnet.com/1007-9327/full/v22/i25/5623.htm
DOI	http://dx.doi.org/10.3748/wjg.v22.i25.5623

Full Article (PDF)	WJG-22-5623.pdf
Full Article (Word)	WJG-22-5623.doc
Manuscript File	27006-Reveiw.docx
Answering Reviewers	27006-Answering reviewers.pdf
Audio Core Tip	27006-Audio core tip.aif
Conflict-of-Interest Disclosure Form	27006-Conflict-of-interest statement.pdf
Copyright License Agreement	27006-Copyright assignment.pdf
Peer-review Report	27006-Peer-review(s).pdf
Scientific Misconduct Check	27006-Scientific misconduct check.pdf
Scientific Editor Work List	27006-Scientific editor work list.pdf